Additionally, the FDA has approved B cell maturation antigen (BCMA)-targeted CAR-T cells for relapsed/refractory multiple myeloma, which have shown overall response rates of 73–98% [31,32]. Here, TNFRSF17 is linked to plasma cell myeloma.